350 related articles for article (PubMed ID: 31468286)
1. Long Non-coding RNA Expression in Anaplastic Thyroid Carcinomas.
Wang Y; Hardin H; Chu YH; Esbona K; Zhang R; Lloyd RV
Endocr Pathol; 2019 Dec; 30(4):262-269. PubMed ID: 31468286
[TBL] [Abstract][Full Text] [Related]
2. Long Non-coding RNA Linc-ROR Is Upregulated in Papillary Thyroid Carcinoma.
Zhang R; Hardin H; Huang W; Buehler D; Lloyd RV
Endocr Pathol; 2018 Mar; 29(1):1-8. PubMed ID: 29280051
[TBL] [Abstract][Full Text] [Related]
3. In Situ Hybridization Analysis of miR-146b-5p and miR-21 in Thyroid Nodules: Diagnostic Implications.
Guo Z; Hardin H; Montemayor-Garcia C; Asioli S; Righi A; Maletta F; Sapino A; Lloyd RV
Endocr Pathol; 2015 May; 26(2):157-63. PubMed ID: 25771986
[TBL] [Abstract][Full Text] [Related]
4. MALAT1 Long Non-coding RNA Expression in Thyroid Tissues: Analysis by In Situ Hybridization and Real-Time PCR.
Zhang R; Hardin H; Huang W; Chen J; Asioli S; Righi A; Maletta F; Sapino A; Lloyd RV
Endocr Pathol; 2017 Mar; 28(1):7-12. PubMed ID: 27696303
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
[TBL] [Abstract][Full Text] [Related]
6. Transcript-level regulation of MALAT1-mediated cell cycle and apoptosis genes using dual MEK/Aurora kinase inhibitor "BI-847325" on anaplastic thyroid carcinoma.
Samimi H; Haghpanah V; Irani S; Arefian E; Sohi AN; Fallah P; Soleimani M
Daru; 2019 Jun; 27(1):1-7. PubMed ID: 31077090
[TBL] [Abstract][Full Text] [Related]
7. Long noncoding RNA landscapes specific to benign and malignant thyroid neoplasms of distinct histological subtypes.
Yakushina VD; Strelnikov VV; Tanas AS; Lavrov AV
Sci Rep; 2021 Aug; 11(1):16728. PubMed ID: 34408227
[TBL] [Abstract][Full Text] [Related]
8. FUCA1 is induced by wild-type p53 and expressed at different levels in thyroid cancers depending on p53 status.
Tsuchida N; Ikeda MA; Ιshino Υ; Grieco M; Vecchio G
Int J Oncol; 2017 Jun; 50(6):2043-2048. PubMed ID: 28440416
[TBL] [Abstract][Full Text] [Related]
9. EIF5A2 Is Highly Expressed in Anaplastic Thyroid Carcinoma and Is Associated With Tumor Growth by Modulating TGF- Signals.
Hao F; Zhu Q; Lu L; Sun S; Huang Y; Zhang J; Liu Z; Miao Y; Jiao X; Chen D
Oncol Res; 2020 Sep; 28(4):345-355. PubMed ID: 32138807
[TBL] [Abstract][Full Text] [Related]
10. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
11. Cell Cycle M-Phase Genes Are Highly Upregulated in Anaplastic Thyroid Carcinoma.
Weinberger P; Ponny SR; Xu H; Bai S; Smallridge R; Copland J; Sharma A
Thyroid; 2017 Feb; 27(2):236-252. PubMed ID: 27796151
[TBL] [Abstract][Full Text] [Related]
12. Genomic amplification of long noncoding RNA HOTAIRM1 drives anaplastic thyroid cancer progression via repressing miR-144 biogenesis.
Zhang L; Zhang J; Li S; Zhang Y; Liu Y; Dong J; Zhao W; Yu B; Wang H; Liu J
RNA Biol; 2021 Apr; 18(4):547-562. PubMed ID: 32951513
[TBL] [Abstract][Full Text] [Related]
13. TROP-2 expression in papillary thyroid carcinoma: Potential Diagnostic Utility.
Simms A; Jacob RP; Cohen C; Siddiqui MT
Diagn Cytopathol; 2016 Jan; 44(1):26-31. PubMed ID: 26481593
[TBL] [Abstract][Full Text] [Related]
14. High expression of CD10 in anaplastic thyroid carcinomas.
Nakazawa T; Kondo T; Vuong HG; Odate T; Kawai M; Tahara I; Kasai K; Inoue T; Oishi N; Mochizuki K; Ito K; Katoh R
Histopathology; 2018 Sep; 73(3):492-499. PubMed ID: 29791034
[TBL] [Abstract][Full Text] [Related]
15. TROP-2, 5hmC, and IDH1 Expression in Anaplastic Thyroid Carcinoma.
Seok JY; Astvatsaturyan K; Peralta-Venturina M; Lai J; Fan X
Int J Surg Pathol; 2021 Jun; 29(4):368-377. PubMed ID: 33289434
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA 483-3p targets Pard3 to potentiate TGF-β1-induced cell migration, invasion, and epithelial-mesenchymal transition in anaplastic thyroid cancer cells.
Zhang X; Liu L; Deng X; Li D; Cai H; Ma Y; Jia C; Wu B; Fan Y; Lv Z
Oncogene; 2019 Jan; 38(5):699-715. PubMed ID: 30171257
[TBL] [Abstract][Full Text] [Related]
17. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Landa I; Ibrahimpasic T; Boucai L; Sinha R; Knauf JA; Shah RH; Dogan S; Ricarte-Filho JC; Krishnamoorthy GP; Xu B; Schultz N; Berger MF; Sander C; Taylor BS; Ghossein R; Ganly I; Fagin JA
J Clin Invest; 2016 Mar; 126(3):1052-66. PubMed ID: 26878173
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of the mitotic spindle assembly checkpoint genes hBUB1, hBUBR1 and hMAD2 in thyroid carcinomas with aggressive nature.
Wada N; Yoshida A; Miyagi Y; Yamamoto T; Nakayama H; Suganuma N; Matsuzu K; Masudo K; Hirakawa S; Rino Y; Masuda M; Imada T
Anticancer Res; 2008; 28(1A):139-44. PubMed ID: 18383837
[TBL] [Abstract][Full Text] [Related]
19. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma.
Wang HM; Huang YW; Huang JS; Wang CH; Kok VC; Hung CM; Chen HM; Tzen CY
Ann Surg Oncol; 2007 Oct; 14(10):3011-8. PubMed ID: 17638058
[TBL] [Abstract][Full Text] [Related]
20. TWIST1/miR-584/TUSC2 pathway induces resistance to apoptosis in thyroid cancer cells.
Orlandella FM; Di Maro G; Ugolini C; Basolo F; Salvatore G
Oncotarget; 2016 Oct; 7(43):70575-70588. PubMed ID: 27661106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
